LYMPHOMA, B-CELL
Clinical trials for LYMPHOMA, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, B-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test 'Double-Punch' immune cell therapy for tough blood cancers
Disease control OngoingThis early-stage trial is testing a new type of CAR-T cell therapy designed to fight B-cell cancers like leukemia and lymphoma. The therapy modifies a patient's own immune T-cells to hunt and kill cancer cells by targeting two proteins (CD19 and CD20) on the cancer's surface. The…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Gentler chemo tested for elderly lymphoma patients
Disease control OngoingThis study is testing a modified, potentially less harsh chemotherapy combination for patients aged 75 and older with an aggressive type of blood cancer called DLBCL. The goal is to see if adding a targeted drug (polatuzumab vedotin) to a reduced-dose standard regimen is effectiv…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test 'Kill Switch' in Cancer-Fighting immune cells
Disease control OngoingThis early-stage study is testing the safety of a new type of personalized cell therapy for adults with B-cell lymphoma that has come back or not responded to other treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better target cancer, and …
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Lifeline for cancer patients: extended drug access trial
Disease control OngoingThis study provides continued access to the cancer drug ibrutinib for patients who benefited from it in previous clinical trials but cannot obtain it through regular commercial channels. It allows about 300 patients with various blood cancers or solid tumors to keep receiving the…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE4 • Sponsor: Pharmacyclics Switzerland GmbH • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New cell therapy tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new cell therapy called FT819. It is for adults with B-cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. Researchers are giving FT819 alone or combined with another drug…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Personalized chemo dose could reduce side effects in lymphoma transplant patients
Disease control OngoingThis study is testing a new, personalized way to calculate the dose of melphalan chemotherapy given to lymphoma patients before a stem cell transplant. Instead of using a standard dose based on height and weight, researchers are using a mathematical model to calculate an optimal …
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope pill tested for lymphoma that Won't quit
Disease control OngoingThis study is testing an experimental daily pill called valemetostat for adults whose B-cell lymphoma has returned or hasn't responded to standard treatments. The main goal is to see how well the drug shrinks tumors and how safe it is for patients who have few other options. Abou…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New pill tested as potential lifeline for Tough-to-Treat blood cancers
Disease control OngoingThis study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC